Findings reinforce the multi-tumor potential of KIF18A inhibitor, ATX-295, in high-grade serous ovarian, squamous non-small cell lung, and triple-negative breast cancer models

研究结果加强了KIF18A抑制剂ATX-295在高级别浆液性卵巢癌、鳞状非小细胞肺癌和三阴性乳腺癌模型中的多肿瘤潜力。

LEXINGTON, Mass.

马萨诸塞州列克星敦

,

，

April 2, 2026

2026年4月2日

/PRNewswire/ -- Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel small molecule precision cancer therapies, today announced that it will present data supporting its potentially best-in-class KIF18A inhibitor, ATX-295, in a poster presentation at the 2026 AACR Annual Meeting taking place April 17-22 in San Diego, California..

/PRNewswire/ -- Accent Therapeutics是一家处于临床阶段的生物制药公司，致力于开发新型小分子精准癌症疗法。该公司今日宣布，将在2026年4月17日至22日于加利福尼亚州圣地亚哥举行的AACR年会上，通过海报展示的形式公布支持其潜在同类最佳KIF18A抑制剂ATX-295的数据。

The poster presentation will feature robust

海报展示将具有强大的特点

in vitro

体外

and

和

in vivo

体内

data demonstrating ATX-295's anti-tumor activity in models of high-grade serous ovarian cancer (HGSOC), squamous non-small cell lung cancer (sqNSCLC), and triple-negative breast cancer (TNBC). Accent's lead program, ATX-295, is designed to target cancer vulnerabilities derived from genomic and chromosomal instability.

ATX-295在高级别浆液性卵巢癌（HGSOC）、鳞状非小细胞肺癌（sqNSCLC）和三阴性乳腺癌（TNBC）模型中展示抗肿瘤活性的数据。Accent的主导项目ATX-295旨在靶向由基因组和染色体不稳定性引发的癌症脆弱性。

These aggressive tumor types share a high prevalence of such instability, representing a large patient population and strong rationale for KIF18A inhibition..

这些侵袭性肿瘤类型具有这种不稳定的高发生率，代表着庞大的患者群体，也为抑制KIF18A提供了有力的理由。

By selectively targeting this dependency, ATX-295 drives rapid cell death in cancer cells burdened with genomic and chromosomal abnormalities, while leaving healthy cells unaffected. The program is currently being evaluated in a Phase 1/2 open-label study enrolling patients with locally advanced or metastatic solid tumors..

通过有针对性地攻击这种依赖性，ATX-295能够快速导致携带基因组和染色体异常的癌细胞死亡，同时不会影响健康细胞。该项目目前正在一项1/2期开放标签研究中进行评估，受试者为局部晚期或转移性实体瘤患者。

'Patients with aggressive, chromosomally instable tumors like squamous non-small cell lung, high-grade serous ovarian, and triple-negative breast cancer face limited durable treatment options and a high risk of disease progression,' said Serena Silver, Ph.D., Chief Scientific Officer at Accent Therapeutics.

“患有侵袭性、染色体不稳定的肿瘤患者，如鳞状非小细胞肺癌、高级别浆液性卵巢癌和三阴性乳腺癌，面临着有限的持久治疗选择和高疾病进展风险，”Accent Therapeutics首席科学官Serena Silver博士说道。

'We are particularly encouraged by these new preclinical findings, which demonstrate compelling activity in squamous lung models. We believe this dataset further supports the potential of our program to address a significant unmet need and reinforces our commitment to advancing innovative therapies for patients who urgently require better options.'.

“我们对这些新的临床前研究结果感到特别鼓舞，这些结果展示了在鳞状肺癌模型中的显著活性。我们相信这一数据集进一步支持了我们的项目解决重大未满足需求的潜力，并且坚定了我们为迫切需要更好治疗选择的患者推进创新疗法的决心。”

Presentation details are as follows:

演示详情如下：

Poster Title:

海报标题：

Robust anti-tumor activity of the novel KIF18A inhibitor, ATX-295, in preclinical models of chromosomally instable tumors

染色体不稳定的肿瘤临床前模型中，新型KIF18A抑制剂ATX-295的强效抗肿瘤活性

Abstract Number

摘要编号

: 6641

: 6641

Session Title

会话标题

: Multi-Axis Antineopastic Agents

多轴抗肿瘤药物

Session Date and Time

会话日期和时间

: Tuesday, April 21, 2:00 PM – 5:00 PM PT

：4月21日星期二，下午2:00 – 下午5:00（太平洋时间）

Location:

位置：

Poster Section 14

海报部分 14

Poster Board Number

海报板编号

: 2

：2

Presenter

主持人

: Laura Ghisolfi, Ph.D.

: 劳拉·吉索菲，博士

About ATX-295

关于ATX-295

Accent's lead program, ATX-295, is a potential best-in-class inhibitor for KIF18A, a mitotic kinesin motor protein critical for cell division in select tumors with chromosomal instability. KIF18A inhibitor treatment results in rapid cell death for cancers with an abnormal number of chromosomes (aneuploid) .

Accent公司的主要项目ATX-295是一种潜在的同类最佳KIF18A抑制剂，KIF18A是一种在具有染色体不稳定性的特定肿瘤中对细胞分裂至关重要的有丝分裂驱动蛋白。KIF18A抑制剂治疗会导致染色体数量异常（非整倍体）的癌细胞快速死亡。

in vitro

体外

and

和

in vivo

体内

, while cells with normal numbers of chromosomes (euploid) are unaffected. ATX-295 may address a large patient population across several cancer indications, including ovarian and squamous non-small cell lung cancer. Accent retains full worldwide rights to the KIF18A program, currently being evaluated in an ongoing Phase 1/2 clinical study .

，而染色体数目正常的细胞（整倍体）则不受影响。 ATX-295可能针对多种癌症适应症的广大患者群体，包括卵巢癌和鳞状非小细胞肺癌。 Accent保留了KIF18A项目的全球全部权利，该项目目前正在一项正在进行的1/2期临床研究中进行评估。

(NCT06799065)

(NCT06799065)

enrolling patients with locally advanced or metastatic solid tumors, including high-grade serous ovarian cancer and squamous non-small cell lung cancer.

招收局部晚期或转移性实体瘤患者，包括高级别浆液性卵巢癌和鳞状非小细胞肺癌。

About Accent Therapeutics

关于Accent Therapeutics

Accent Therapeutics is a clinical-stage biopharmaceutical company pioneering novel small molecule precision cancer therapies. Accent is leveraging its industry-leading expertise to prosecute novel tumor vulnerabilities in cancers with high genomic and chromosomal instability. Accent's innovative therapies are designed for high-impact oncology targets with the potential to benefit large patient populations with significant unmet need.

Accent Therapeutics是一家处于临床阶段的生物制药公司，致力于开发新型小分子精准癌症疗法。Accent凭借其行业领先的专业知识，针对具有高基因组和染色体不稳定性癌症中的新型肿瘤脆弱性进行研究。Accent的创新疗法专注于高影响力的肿瘤学靶点，有望为存在巨大未满足需求的广大患者群体带来益处。

The company's lead program — ATX-295, targeting KIF18A — is currently being evaluated in Phase 1/2 clinical studies. For more information on Accent's mission to translate extraordinary science into life-changing therapeutics for patients living with cancer, visit .

该公司的主要项目——针对KIF18A的ATX-295——目前正在1/2期临床研究中进行评估。如需了解更多关于Accent公司致力于将非凡科学转化为改变生命的癌症治疗药物的信息，请访问。

www.accenttx.com

www.accenttx.com

or follow us on

或关注我们

LinkedIn

领英

.

。

Media Contact

媒体联系人

Amanda Sellers, Deerfield Group

阿曼达·塞勒斯，鹿田集团

[email protected]

电子邮件地址

SOURCE Accent Therapeutics

来源：口音治疗公司

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示